A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
Phase 3
Active, not recruiting
NCT06143878
| Condition | Plaque Psoriasis |
|---|
| Phase | Phase 3 |
|---|
| Sponsor | Janssen Research & Development, LLC |
|---|
| Status | Active, not recruiting |
|---|
| Enrollment | 774 participants |
|---|
| Interventions | JNJ-77242113, JNJ-77242113 Matching Placebo, Deucravacitinib, Deucravacitinib Matching Placebo |
|---|
| Start date | Feb 1, 2024 |
|---|
| Completion date | Sep 17, 2024 |
|---|
| Results posted | Jun 25, 2026 |
|---|
Summary
The purpose of the study is to see how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.
Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of 0 or 1 and a Greater Than or Equal to (>=) 2-Grade Improvement From Baseline at Week 16
Week 16 · Percentage of participants
| Arm 1: Placebo Followed by JNJ-77242113 200 mg | 10.9 Percentage of participants |
|---|
| Arm 2: JNJ-77242113 200 mg | 68.5 Percentage of participants |
|---|
| p-value | <0.001 |
|---|
| Treatment difference | 57.6 (95% CI 49.9–64.2) |
|---|
Percentage of Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 at Week 16
Week 16 · Percentage of participants
| Arm 1: Placebo Followed by JNJ-77242113 200 mg | 3.8 Percentage of participants |
|---|
| Arm 2: JNJ-77242113 200 mg | 55.0 Percentage of participants |
|---|
| p-value | <0.001 |
|---|
| Treatment difference | 51.2 (95% CI 44.5–57.3) |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
Other trials for this condition
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.